Catalyst Biosciences, Inc. announced that the appointment of Edward Williams to the board of directors, effective Jan. 1, 2018. Mr. Williams was most recently senior vice president of biopharmaceuticals at Novo Nordisk Inc., where he was responsible for the general management of all aspects of the biotechnology business for the U.S. in three therapeutic areas, including hemophilia. Dr. Barry Selick, who has been a Catalyst board member since 2003 and chairman since 2006, will step down from the board effective Feb. 15, 2018. Dr. Selick was recently named vice chancellor of business development, innovation and partnerships at the University of California, San Francisco. Current board member Augustine Lawlor will replace Dr. Selick as chairman.